Latest news

• Orphan drugs from Biogen and Amicus win UK Prix Galien

  Sanofi’s treatment for moderate-to-severe atopic dermatitis Dupixent was highly commended in the same category.

• Dupixent helps put Sanofi back on growth track

  and delivered on its promise thanks to a surge in sales for atopic dermatitis drug Dupixent. ... Dupixent (dupilumab) – which has also just been approved for asthma – saw sales almost triple to 225m in the three-month period, helping Sanofi’s net

• AZ, Amgen’s first-in-class asthma drug gets breakthrough status

  Regeneron’s new candidate Dupixent (dupilumab), an IL-4 and IL-13 inhibitor that is already approved for atopic dermatitis. ... Dupixent was filed for asthma in the US in March and is due for an FDA verdict by 20 October, but some analysts have said

• Dupixent bounce-back helps stem diabetes declines at Sanofi

  CEO Brandicourt says Sanofi will “enter a new growth phase”. A sudden uptick in sales of atopic dermatitis drug Dupixent helped offset a steep decline in diabetes sales at Sanofi in ... Leading the charge in the specialty care category this quarter

• Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO

  There is plenty of competition in the field, with Pfizer’s Eucrisa and Regeneron and Sanofi’s Dupixent already on the market.